

Bob LÃ¶wenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1908095/publications.pdf>

Version: 2024-02-01

143
papers

22,521
citations

44444

50
h-index

27587

110
g-index

145
all docs

145
docs citations

145
times ranked

21027
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	0.6	4,375
2	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649.	0.8	2,425
3	Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. <i>Cancer Cell</i> , 2010, 18, 553-567.	7.7	2,328
4	Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2004, 350, 1617-1628.	13.9	1,232
5	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2009, 113, 1875-1891.	0.6	856
6	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
7	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	0.6	805
8	High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2009, 361, 1235-1248.	13.9	745
9	DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2010, 17, 13-27.	7.7	737
10	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1189-1199.	13.9	605
11	A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia. <i>Cell</i> , 2014, 157, 369-381.	13.5	571
12	Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype. <i>Journal of Clinical Oncology</i> , 2008, 26, 4791-4797.	0.8	517
13	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	0.6	393
14	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3889-3897.	0.8	392
15	Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 349, 743-752.	13.9	356
16	Cytarabine Dose for Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 1027-1036.	13.9	343
17	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016, 22, 792-799.	15.2	322
18	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. <i>Blood</i> , 2018, 131, 2661-2669.	0.6	313

#	ARTICLE	IF	CITATIONS
19	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010, 115, 5137-5146.	0.6	278
20	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	0.6	183
21	How I treat the older patient with acute myeloid leukemia. <i>Blood</i> , 2015, 125, 767-774.	0.6	177
22	Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2014, 9, e107587.	1.1	164
23	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , 2008, 112, 3130-3134.	0.6	154
24	Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. <i>Blood</i> , 2013, 121, 26-28.	0.6	143
25	miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. <i>Nature Communications</i> , 2012, 3, 688.	5.8	138
26	Towards precision medicine for AML. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 577-590.	12.5	138
27	Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. <i>Blood</i> , 2010, 115, 2586-2591.	0.6	131
28	Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood</i> , 2022, 139, 2347-2354.	0.6	131
29	CD34+CD38 ⁺ leukemic stem cell frequency to predict outcome in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1102-1112.	3.3	130
30	Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. <i>Blood</i> , 2019, 133, 1457-1464.	0.6	125
31	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. <i>Blood</i> , 2021, 137, 1792-1803.	0.6	123
32	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	117
33	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011, 117, 1799-1805.	0.6	112
34	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	0.6	103
35	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011, 117, 4561-4568.	0.6	99
36	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , 2013, 121, 1935-1943.	0.6	96

#	ARTICLE	IF	CITATIONS
37	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019, 133, 1140-1151.	0.6	96
38	Including historical data in the analysis of clinical trials: Is it worth the effort?. <i>Statistical Methods in Medical Research</i> , 2018, 27, 3167-3182.	0.7	93
39	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. <i>Blood</i> , 2018, 132, 1526-1534.	0.6	90
40	Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 1-11.	0.9	89
41	Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. <i>Blood</i> , 2015, 125, 133-139.	0.6	86
42	Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. <i>Blood</i> , 2012, 119, 5367-5373.	0.6	85
43	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. <i>Blood Advances</i> , 2020, 4, 5011-5024.	2.5	85
44	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010, 95, 424-431.	1.7	84
45	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. <i>Blood</i> , 2017, 129, 1636-1645.	0.6	77
46	Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2461-2466.	0.6	71
47	Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2010, 28, 4333-4338.	0.8	67
48	Minimal Residual Disease in Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 349, 1399-1401.	13.9	59
49	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011, 96, 1470-1477.	1.7	59
50	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010.	0.8	58
51	Sustainability and affordability of cancer drugs: a novel pricing model. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 405-406.	12.5	55
52	Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2017, 130, 637-637.	0.6	49
53	Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2985-2994.	0.6	42
54	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. <i>Blood</i> , 2015, 126, 2547-2547.	0.6	42

#	ARTICLE	IF	CITATIONS
55	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	2.0	36
56	MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. <i>Blood</i> , 2016, 128, 2253-2257.	0.6	34
57	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. <i>Blood Advances</i> , 2021, 5, 1110-1121.	2.5	33
58	Phase 1 Cohort Expansion of Flotetuzumab, a CD123-CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 764-764.	0.6	32
59	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.	0.8	31
60	High β -Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2302-2306.	0.6	28
61	Acute myeloid leukemia and acute promyelocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2003, , 82-101.	0.9	26
62	Double, but Not Single, CEBPA mutations Define a Subgroup of Acute Myeloid Leukemia with Favorable Outcome and a Distinct Gene Expression Profile. <i>Blood</i> , 2008, 112, 141-141.	0.6	24
63	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.	0.6	21
64	Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. <i>Haematologica</i> , 2016, 101, e284-e286.	1.7	18
65	Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 - CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 444-444.	0.6	18
66	<i>RUNX1</i> germline variants in <i>RUNX1</i> -mutant AML: how frequent?. <i>Blood</i> , 2021, 137, 1428-1431.	0.6	15
67	Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	14
68	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. <i>Blood Advances</i> , 2020, 4, 4267-4277.	2.5	14
69	Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2019, 134, 733-733.	0.6	14
70	Prognostic impact of <i>KMT2E</i> transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , 2014, 166, 540-549.	1.2	13
71	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 1146-1155.	0.6	12
72	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 16-18.	0.6	12

#	ARTICLE	IF	CITATIONS
73	Sex disparity in acute myeloid leukaemia with <i>FLT3</i> internal tandem duplication mutations: implications for prognosis. <i>Molecular Oncology</i> , 2021, 15, 2285-2299.	2.1	11
74	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. <i>Blood</i> , 2009, 114, 6-6.	0.6	11
75	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. <i>Haematologica</i> , 2015, 100, e409-e411.	1.7	10
76	The Growth Factor Independence 1 variant form GFI136N Predisposes to Acute Myeloid Leukemia by Inducing Epigenetic Changes in Oncogenes Such As Hoxa9. <i>Blood</i> , 2011, 118, 223-223.	0.6	10
77	Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML. <i>Blood</i> , 2017, 130, LBA-5-LBA-5.	0.6	10
78	An analysis of the impact of CD56 expression in <i>de novo</i> acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019, 60, 1030-1035.	0.6	9
79	Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific DART® Molecule for T-Cell Redirected Therapy. <i>Blood</i> , 2018, 132, 2738-2738.	0.6	9
80	A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. <i>Experimental Hematology and Oncology</i> , 2013, 2, 7.	2.0	8
81	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1807-1814.	2.5	8
82	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 2442-2443.	13.9	7
83	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , 2020, 12, 3134.	1.7	7
84	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. <i>Cancers</i> , 2021, 13, 672.	1.7	7
85	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020, 104, 162-169.	1.1	6
86	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 10315.	1.6	5
87	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. <i>Blood</i> , 2020, 136, 19-21.	0.6	5
88	Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2080-2080.	0.6	5
89	Introduction to a review series on myelodysplastic syndromes. <i>Blood</i> , 2019, 133, 1001-1001.	0.6	4
90	DNA vs cDNA <i>FLT3</i> -ITD allelic ratio and length measurements in adult acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4476-4479.	2.5	4

#	ARTICLE	IF	CITATIONS
91	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy. <i>Blood</i> , 2019, 134, 5144-5144.	0.6	4
92	Dirk Willem van Bakkum: a pioneer in haematology, transplantation and radiobiology (1925–2015). <i>Leukemia</i> , 2015, 29, 2275-2276.	3.3	3
93	Overall survival by <i>IDH2</i> mutant allele (R140 or R172) in patients with late-stage mutant- <i>IDH2</i> relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 7005-7005.	0.8	3
94	The long road: improving outcome in elderly ‘unfit’ AML. <i>Blood</i> , 2020, 135, 2114-2115.	0.6	2
95	PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse. <i>Leukemia</i> , 2021, 35, 2693-2697.	3.3	2
96	Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123–CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 460-460.	0.6	2
97	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 306-306.	0.6	2
98	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013, 122, 64-64.	0.6	2
99	Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 588-588.	12.5	1
100	A Novel Subgroup of Poor Prognostic AML with Low CEBPA Expression, CEBPA Promoter Hypermethylation and DNMT3b Overexpression. <i>Blood</i> , 2004, 104, 418-418.	0.6	1
101	Genetic vs. Epigenetic Disruption of the CEBPA Locus Yields Epigenomically and Biologically Distinct Leukemia Phenotypes. <i>Blood</i> , 2007, 110, 2117-2117.	0.6	1
102	Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab. <i>Blood</i> , 2011, 118, 1555-1555.	0.6	1
103	Acceleration and Enhancement of T-Cell Recovery and Immune Competence by Flt3-Ligand (Flt3L) Following BMT with Low Numbers of Progenitor Cells in Immune Deficient Mice. <i>Blood</i> , 2004, 104, 47-47.	0.6	1
104	High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome. <i>Blood</i> , 2007, 110, 4297-4297.	0.6	1
105	VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles. <i>Blood</i> , 2009, 114, 997-997.	0.6	1
106	Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse. <i>Blood</i> , 2009, 114, 1062-1062.	0.6	1
107	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning. <i>Blood</i> , 2011, 118, 159-159.	0.6	1
108	DNMT3A Mutations Enhance CpG Mutagenesis through Dereglulation of the Active DNA Demethylation Pathway. <i>Blood</i> , 2016, 128, 1076-1076.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation. <i>Blood</i> , 2021, 138, 1276-1276.	0.6	1
110	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123Ä—CD3 Bispecific DartÄ® Molecule, in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-28.	0.6	1
111	Dick W. van Bekkum, 1925-2015. <i>Transplantation</i> , 2015, 99, 2442-2443.	0.5	0
112	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017, 1, 86-89.	2.5	0
113	Reply to ÄResponse to proposal for a novel cancer drug pricing modelÄ™. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 528-529.	12.5	0
114	Professor Anton Hagenbeek 1948Ä—2021: Father of MRD and lymphoma expert. <i>Bone Marrow Transplantation</i> , 2021, 56, 2038-2039.	1.3	0
115	Clinical Useful Prognostic Index for Adult Patients with Acute Myeloid Leukemia in First Relapse.. <i>Blood</i> , 2004, 104, 2011-2011.	0.6	0
116	Pathogenetic Significance of Retrovirus-Tagged Mouse Myeloid Leukemia Genes for Human AML.. <i>Blood</i> , 2004, 104, 468-468.	0.6	0
117	A Two-Gene Classifier for Predicting Response to the Farnesyltransferase Inhibitor Tipifarnib in Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 1445-1445.	0.6	0
118	DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 707-707.	0.6	0
119	High Prognostic Impact of Mixed Chimerism of Blood and Marrow In the First Year After Allogeneic Hematopoietic Stem Cell Transplantation: The Need to Rapidly Establish Complete Donor Chimerism.. <i>Blood</i> , 2010, 116, 3464-3464.	0.6	0
120	CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies. <i>Blood</i> , 2010, 116, 3279-3279.	0.6	0
121	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,. <i>Blood</i> , 2011, 118, 3552-3552.	0.6	0
122	ÄNp73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,. <i>Blood</i> , 2011, 118, 3536-3536.	0.6	0
123	Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML. <i>Blood</i> , 2011, 118, 2030-2030.	0.6	0
124	A Single Microarray Assay for Simultaneous Diagnosis of t(15;17), t(8;21), Inv(16)/t(16;16), NPM1 Type A/B/D Mutation, CEBPA Double Mutation, and Aberrant Expression of BAALC or EVI1 in AML/APL Patients. <i>Blood</i> , 2011, 118, 4876-4876.	0.6	0
125	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 236-236.	0.6	0
126	Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias. <i>Blood</i> , 2011, 118, 1441-1441.	0.6	0

#	ARTICLE	IF	CITATIONS
127	The HOXA/PBX3 Pathway Is an Attractive Therapeutic Target in MLL-Rearranged Acute Leukemia. Blood, 2012, 120, 3522-3522.	0.6	0
128	The Gene Encoding Nuclear Erythroid Factor 2 (NFE2) Is Recurrently Mutated in Acute Myeloid Leukemia. Blood, 2012, 120, 1392-1392.	0.6	0
129	BAALC and EVI1 Prognostic Gene Expression in Adult Acute Myeloid Leukemia Using the Amlprofiler Custom Microarray. Blood, 2012, 120, 1420-1420.	0.6	0
130	Prognostic and Functional Relevance of Aberrant Microrna-9/9* Expression in Acute Myeloid Leukemia.. Blood, 2012, 120, 2542-2542.	0.6	0
131	Cfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia. Blood, 2013, 122, 2516-2516.	0.6	0
132	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 303-303.	0.6	0
133	PU.1 Is Essential For MLL Leukemia Via Activation Of The Meis/HOX Pathway and A Monocytic Cytokine Mediated Anti-Apoptotic Inflammatory Program. Blood, 2013, 122, 1276-1276.	0.6	0
134	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2013, 122, 2586-2586.	0.6	0
135	Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage. Blood, 2014, 124, 1067-1067.	0.6	0
136	Defects in the RAS/RTK Signaling Pathways Predominate the Mutational Spectrum of EVI1/GATA2 Rearranged Myeloid Malignancies with Inv(3)/t(3;3). Blood, 2014, 124, 701-701.	0.6	0
137	Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. Blood, 2014, 124, 3676-3676.	0.6	0
138	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. Blood, 2016, 128, 3467-3467.	0.6	0
139	Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.. Journal of Clinical Oncology, 2018, 36, 7045-7045.	0.8	0
140	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. Blood, 2018, 132, 1533-1533.	0.6	0
141	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 2719-2719.	0.6	0
142	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 5166-5166.	0.6	0
143	<i>TP53</i> Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. Blood, 2020, 136, 3-4.	0.6	0